2019 Great Lakes Biomedical Conference in conjunction with the Rocky Mountain Bioengineering Symposium

Share

This special joint meeting of the Great Lakes Biomedical Conference and Rocky Mountain Bioengineering Symposium will bring together researchers delivering technical talks in areas spanning biomedical engineering, from biomechanics to biosignal processing. In addition, a series of keynote presentations and special panel session will be devoted to Translation of Medical Devices: From Idea to MarketStudents will compete in poster presentations describing their research and senior design projects. Finally, networking opportunities will allow participants to meet with colleagues, new and old, local and beyond. 

The event will feature a special panel session from 5:30-6:30pm on Friday, April 12, entitled Founders Forum: What You Know Now that You Wish You Knew Then, powered by HealthTechMKE.

  Moderator: Milton Hwang (Senior Director, Connecture)

  Panelists: Scott Bolte (Founder, Trailhead Clinical Strategies, LLC), Lars Olson (Founder, Cortina Medical Devices, LLC), Amanda Baltz (CEO, Spaulding Medical)

 



  Date and Time

  Location

  Contact

  Registration



  • Milwaukee School of Engineering
  • 1047 North Broadway
  • Milwaukee, Wisconsin
  • United States 53202
  • Building: Todd Wehr Conference Center
  • Click here for Map

Staticmap?size=250x200&sensor=false&zoom=14&markers=43.0441245%2c 87
  • Co-sponsored by Rocky Mountain Bioengineering Symposium


  Speakers

Dr. Aoy Tomita-Mitchell

Dr. Aoy Tomita-Mitchell of Medical College of Wisconsin

Topic:

The Promise of Genetic Research in Congenital Heart Disease in Children

Biography:

Aoy Tomita-Mitchell, PhD is a Professor in the Department of Surgery, Division of Pediatric Cardiothoracic Surgery at the Medical College of Wisconsin and investigator at the Children’s Research Institute.  Her laboratory investigates underlying genetic risk factors of congenital heart disease and is interested in understanding how genetic alterations can impact molecular pathways, resulting in clinical variability.  The lab has also conducted pioneering research on circulating cell free DNA.  Dr. Tomita-Mitchell has received numerous grants and has numerous publications.  She is a co-founder of two biotechnology startup companies, TAI Diagnostics (based in Milwaukee) and Ariosa Diagnostics (San Jose, CA), which was acquired by Roche in January 2015. Aoy graduated from the Massachusetts Institute of Technology where she studied mechanical engineering as an undergraduate and where she also received her PhD in bioengineering in the field of genetic toxicology.  She worked in industry and then returned to academia at the Children’s Hospital of Philadelphia as a postdoctoral fellow in pediatric cardiac genetics.

Dr. Kip Ludwig
Dr. Kip Ludwig of University of Wisconsin-Madison

Topic:

Developing an Ecosystem for Parallel Translation of Medical Devices

Perspectives from a Career in Industry, Government, and Academia

Biography:

Dr. Kip Ludwig leads the Bioelectronic Medicines Laboratory at the University of Wisconsin. The primary focus of his lab is developing next-generation neuromodulation therapies that use minimally invasive strategies to ‘wiretap’ the nervous system to treat circuit dysfunction and deliver biomolecules to target areas with unprecedented precision. Prior to Wisconsin Dr. Ludwig served as the Program Director for Neural Engineering at the National Institutes of Health. He co-led the Translational Devices Program at NINDS, led the White House NIH BRAIN Initiative programs to catalyze implantable academic and clinical devices to stimulate and/or record from the central nervous system, and led a trans-NIH planning team in developing the ~250 million dollar S.P.A.R.C. Program to stimulate advances in neuromodulation therapies for organ systems. Dr. Ludwig also worked in Industry as a research scientist, where his team conceived, developed and demonstrated the chronic efficacy of a next-generation neural stimulation electrode for reducing blood pressure in both pre-clinical studies and clinical trials. Through his industry work he oversaw Good Laboratory Practice (GLP) and non-GLP studies enabling clinical trials in Europe and the United States, as well as participated in the protocol development and execution of those trials, leading to approval for sale in seven countries and a U.S. Pivotal trial.

 





Agenda

A full conference schedule can be found at https://rmbs.org/